Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial
In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moder...
Saved in:
Main Authors: | Michael J. Cork (Author), Benjamin Lockshin (Author), Andreas Pinter (Author), Zhen Chen (Author), Brad Shumel (Author), Randy Prescilla (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
by: Jonathan I. Silverberg, et al.
Published: (2021) -
The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the Global
by: Mads Kirchheiner Rasmussen, et al.
Published: (2018) -
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
by: Andrew Blauvelt, et al.
Published: (2024) -
Patient's perception and importance of clear/almost clear skin in moderate-to-severe plaque psoriasis: Results of clear about psoriasis survey in Taiwan
by: Yu-Huei Huang, et al.
Published: (2019) -
Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023)